Are surrogate markers adequate to assess cardiovascular disease drugs?

JAMA. 1999 Aug 25;282(8):790-5. doi: 10.1001/jama.282.8.790.

Author

R Temple¹

Affiliation

¹ Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20857, USA. Temple@CDER.fda.gov

PMID: 10463719
DOI: 10.1001/jama.282.8.790

No abstract available

MeSH terms

Biomarkers
Cardiovascular Agents* / therapeutic use
Cardiovascular Diseases / prevention & control*
Clinical Trials as Topic*
Drug Approval*
Drug Evaluation
Humans
Risk
Treatment Outcome
United States
United States Food and Drug Administration

Substances

Biomarkers
Cardiovascular Agents